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Abstract:  An  estimated  4  billion  episodes  of  diarrhea  occur  each  year.  As  a  result,  
2–3 million children and 0.5–1 million adults succumb to the consequences of this major 
healthcare  concern.  The  majority  of  these  deaths  can  be  attributed  to  toxin  mediated 
diarrhea by infectious agents, such as E. coli, V. cholerae or Rotavirus. Our understanding 
of  the  pathophysiological  processes  underlying  these  infectious  diseases  has  notably 
improved over the last years. This review will focus on the cellular mechanism of action of 
the most common enterotoxins and the latest specific therapeutic approaches that have 
been developed to contain their lethal effects. 
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1. Introduction 
Diarrhea is widely accepted as a major healthcare concern. However, only closer examination of the 
epidemiological data available to us fully illustrates the massive burden that acute diarrheal illness 
(ADI)  places  on  our  society.  Children  are  particularly  vulnerable  to  the  lethal  effects  of  ADI:  
3.2 episodes of diarrhea occur per child/year in the age group <5 years [1]. A total of 2.5 million ADI 
related deaths worldwide (<5 years) occur each year [1]. This means that one out of five deaths in 
children (<5 years) is caused by diarrhea and is, in theory, preventable [1]. Although the specific 
infectious agent cannot always be identified, the majority of ADI cases are attributable to Rotavirus 
and E. coli infections. 
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In the course of this brief review we will revisit the physiological processes underlying intestinal 
ion transport and proceed to elucidate how prominent enterotoxigenic bacteria manipulate the cellular 
biology to induce diarrhea. This review will focus on two bacterial and one viral agent that will serve 
as  a  pars  pro  toto  for  the  most  common  intracellular  messaging  cascades  that  are  perturbed  by 
enterotoxins: enterotoxigenic E. coli (ETEC) and its heat stable enterotoxin (STa) for cGMP induced 
diarrhea, V. cholerae for cAMP induced diarrhea, and Rotavirus for Ca
2+ induced diarrhea. We will 
additionally  discuss  the  latest  specific  pharmacological  approaches  that  have  been  developed  to 
contain the lethal effects of toxin mediated diarrhea.  
2. The Physiology of Intestinal Ion Transport 
In  order  to  fully  understand  the  pathophysiological  events  that  occur  during  toxin  mediated 
diarrhea, one must appreciate the physiology of intestinal ion and water transport. The enterocyte, 
which is organized in a columnar epithelial monolayer, is responsible for both electrolyte absorption 
and secretion in the intestine. Although intestinal electrolyte secretion mainly occurs in the crypt and 
electrolyte absorption takes place in the villus or surface epithelium, some overlap in terms of function 
is reported to exist between the two regions [2–6]. To account for the conciseness of this overview, the 
term enterocyte will be used without consideration for functional variability within the mucosa or the 
intestine in general.  
2.1. Enterocyte Electrolyte Absorption 
Apical  electrolyte  absorption  by  the  enterocyte  can  be  divided  into  two  major  categories:  
(i) electroneutral absorption and (ii) electrogenic absorption [5].  
Electroneutral  absorption  is  a  synchronized  event  that  involves  Na
+  uptake  by  the  Na
+,  
H
+-Exchanger (NHE) and Cl
− uptake by Cl
−,HCO3
--Exchangers. Currently, nine isoforms of NHE are 
known (for reviews please see [7,8]). NHE1 is located on the basolateral surface of the enterocyte and 
primarily functions as a housekeeping protein for pH and volume homeostasis, whereas NHE2 and 
NHE3 have an apical localization pattern and conduce to bulk Na
+ absorption [5,7,9–13]. Although the 
relative contribution of NHE2 and NHE3, respectively, varies between both species and localization 
within the intestine, NHE3 is thought to be the main mediator of electroneutral Na
+ uptake [7]. This 
assumption is further underscored by the development of NHE2 and NHE3 knockout mouse models. 
In NHE2 (−/−) animals intestinal Na
+ uptake was unaffected. Still, compensatory elevations of NHE3 
mRNA  and  protein  levels  were  reported [14].  Conversely,  NHE3  (−/−)  animals  showed  a  strong 
intestinal phenotype with intestinal hypertrophy and diarrhea, thereby emphasizing the significance of 
NHE3 for physiological salt absorption [14]. Recently, NHE8 has emerged as an important candidate 
for Na
+ absorption in immature animals, which may account for the observed residual Na
+ uptake in 
NHE2/3 (−/−) animals [15,16]. NHE activity is chiefly regulated by cyclic nucleotides, most notably 
cAMP. Elevations in cAMP and activation of protein kinase A (PKA) were both shown to inhibit 
NHE3 [5,7]. For effective inhibition to take place, complex formation with accessory proteins, such as 
NHERF1/2 and the cytoskeleton linker ezrin, is essential [17–19]. A close coupling of NHE activity to 
chloride transport and in particular the cystic fibrosis transmembrane conductance regulator (CFTR) 
channel has also been discussed [20,21]. The importance of this interaction was further supported by Toxins 2010, 2                               
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the ineffectiveness of cAMP in inhibiting Na
+ uptake in CFTR (−/−) animals. Interestingly, it has been 
suggested  that  NHERF1  also  interacts  with  CFTR  and  is  pivotal  for  NHE  inhibition  in  the 
pancreas [22].  CFTR,  NHERF1  and  NHE3  may  thus  form  an  inhibitory  complex  in  response  to 
increased levels of cAMP [22].  
Chloride uptake through apical exchange proteins represents the second component of electroneutral 
absorption. Two members of the solute carrier 26 (SLC26) gene family are expressed on the apical 
enterocyte membrane: SLC26A3 (also known as DRA) and SLC26A6 (also known as PAT1)[23]. PAT1 
expression is predominant in the small intestine, whereas DRA expression is higher in the colon [24,25]. 
Both exchangers can transport HCO3
− in exchange for Cl
−, but their stoichiometry differs in that PAT1 
transports  2  HCO3
−,  whereas  DRA  transports  2  Cl
− [26,27].  Despite  divergent  stoichiometry,  the 
concerted uptake of both exchangers is postulated to be electroneutral. In general, the role of DRA in 
intestinal absorption is better characterized than PAT1. Mutations of DRA are known to be responsible 
for  autosomal  recessive  congenital  chloride  diarrhea  (CLD,  OMIM  214700)[28,29].  CLD  was  first 
described in 1945 in patients exhibiting diarrhea with increased chloride content in the stool. Today, 
more than 250 cases which are mainly clustered in Finland, Poland and Saudi Arabia, have been 
reported and 30 mutations in DRA that are responsible for CLD have been identified [29]. Both PAT1 
and DRA are regulated by CFTR [27,30]. In transfected cells stimulation of CFTR by cAMP leads to a 
six-fold  increase  in  activity  of  both  exchangers [27].  Additionally,  DRA  has  been  shown  to  be 
regulated by intracellular Ca
2+ [31]. Until recently, some controversy persisted regarding the relative 
contribution and importance of DRA and PAT1, respectively [24,32]. Functional studies in DRA and 
PAT1 (−/−) animals have now identified DRA as the predominant mediator of electroneutral chloride 
uptake in the small intestine [30,33]. Members of the SLC4 gene family represent the second type of 
enterocytic anion exchange. SLC4A1 (AE1) localization has been demonstrated on the apical surface 
of colonic enterocytes in the rat [34,35]. These findings could not be reproduced in humans, when 
investigating  mRNA  levels  throughout  the  entire  intestine [36].  The  contribution  of  AE1  to 
physiological  Cl
−  uptake  thus  remains  questionable.  SLC4A9  (AE4)  was  also  identified  in  the 
duodenum, yet subsequent knock-out studies showed that overall HCO3
- transport was decreased by 
only <5% in affected animals [25,37]. 
Electrogenic electrolyte absorption accounts for the second source of apical ion uptake and can 
occur through dedicated channels or through symporters as a byproduct of nutrient absorption. ENaC 
is the most prominent apical Na
+ channel in the colon and allows for Na
+ flux into the cell along its 
electrochemical gradient [5,38]. Comparable to the collecting duct of the kidney, its expression is 
regulated by aldosterone in response to hypovolemia [39]. Interestingly, aldosterone can also induce 
expression  of  ENaC  in  the  small  intestine [40,41].  Its  modulation  by  CFTR  has  been  subject  of 
controversial  discussion  in  the  past [42–45].  It  has  been  suggested  that  an  increase  in  cAMP 
concentrations that in turn activates CFTR has an inhibitory effect on ENaC conductance [42,43,45]. 
However, the expression patterns of both channels in the mucosa do not support this hypothesis, as 
ENaC expression predominates in the colonic surface cells, whereas CFTR is mainly expressed in the 
crypt region [5]. Although this persistent controversy still awaits final clarification, CFTR seems to 
emerge as a potent regulator in nearly all pathways of electrolyte absorption discussed so far.  
The  electrochemical  gradient  that  confers  Na
+  absorption  through  ENaC  is  utilized  by  various 
symporters in the small intestine for secondary active nutrient transport into the enterocyte. Similar to Toxins 2010, 2                               
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its regulation in the kidney, glucose uptake in the proximal small intestine occurs through a member of 
the SGLT symporter family. The stoichiometry of the intestinal isoform (SGLT1) differs from the 
predominant renal isoform (SGLT2), as two Na
+ ions are needed to carry one glucose molecule across 
the apical membrane [46–48]. The WHO issued oral rehydration salts (ORS) solution, which is used as 
a treatment for diarrheal diseases throughout the world, facilitates electrogenic Na
+ uptake through 
SGLT1  by  containing  a  particularly  high  concentration  of  glucose [47,49].  As  water  follows  the 
absorbed electrolytes osmotically, this therapy has proven itself an effective strategy for rehydration.  
Currently,  two  inherited  diseases  that  are  associated  with  SGLT  malfunction  are  known [47]. 
Mutations  in  SGLT1  are  responsible  for  glucose/galactose  malabsorption  (GGM,  OMIM  182380) 
resulting in osmotic diarrhea [50]. The second disorder, i.e., familial renal glucosuria, affects SGLT2 
mediated glucose transport in the kidney [51].  
Amino acid transporters in the small intestine take advantage of the same Na
+ gradient across the 
epithelia to conduct absorption. For a detailed review on the wide variety of involved transporters, 
please refer to a recent review [52]. 
2.2. Enterocyte Electrolyte Secretion 
An estimated eight liters of fluid are being secreted into the intestine on a daily basis [2]. Although 
this fluid is also composed of gastric, pancreatic, and biliary juices as well as saliva, a significant 
portion of the secreted volume is considered to be bona fide enterocyte secretion [2]. Because it is not 
possible for enterocytes to actively transport fluid, secretion is linked to the creation of an osmotic 
gradient that drags water into the intestinal lumen. Apical chloride channels, such as CFTR, are the 
main generators of this osmotic driving force [2]. Chloride secretion through apical channels relies on 
a constant negative membrane potential that is generated by leak current through basolateral potassium 
channels and a steady intracellular concentration of chloride that is maintained by the basolateral Na
+, 
K
+,  2Cl
−  (NKCC)  symporter [2].  Although  these  basolateral  proteins  are  crucial  for  the  secretory 
function of the apical machinery, their review is omitted in the interest of conciseness. For an excellent 
review on chloride secretion, please refer to [2]. 
CFTR is a cAMP regulated chloride channel that is predominantly expressed in the intestinal crypt 
and to a lesser extent in the villus region [53,54]. The channel consists of two membrane spanning 
domains (MSDs), two nucleotide binding domains (NBDs) allowing for hydrolysis of ATP and a 
regulatory  (R)  domain  that  mediates  regulatory  interactions  with  PKA [55].  Regulation  of  CFTR 
mainly occurs through cAMP-dependent PKA at the R domain, but was also shown to be cGMP, PKC, 
c-src and calmodulin dependent [56–62]. In addition to on-site regulation, trafficking rates to the apical 
membrane are affected by cAMP, hence amplifying the impact of cAMP stimulation [63–66]. Recent 
work suggests that the R domain is pivotal for regulatory trafficking to occur [64]. 
Mutations in the CFTR gene result in manifestation of cystic fibrosis (CF), which represents the 
most prevalent genetic disorder in Caucasians. Although the majority of CF symptoms are related to 
respiratory pathologies, gastrointestinal manifestations of the disease are also frequent [67]. Meconium 
ileus, a postnatal intestinal obstruction resulting from hyperviscous stool, is often the first clinical sign 
of CF. The clinical findings and the correlating observations in knock-out animals that succumb to 
intestinal obstruction if not medicated with laxatives emphasize the major role of CFTR in the process Toxins 2010, 2                               
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of  intestinal  chloride/fluid  secretion [67,68].  cAMP  dependent  chloride  secretion  has  been 
demonstrated throughout the intestine using various experimental approaches and has been validated 
by its absence in CFTR mutants [2,3,69–71].  
Ca
2+ activated chloride channels (CaCCs) are extensively described as an alternate chloride efflux 
mechanism in colonic T84 cells [5,72–75]. The role of CaCCs in native human intestinal tissue is, 
however, more ambiguous as several groups reported a failure of intracellular Ca
2+ to increase chloride 
secretion in CF patients [76–78]. Conversely, it has been suggested that a compensatory up regulation 
of CaCCs increases survival in CFTR mutant mice by alleviating symptoms of constipation [79]. The 
molecular identity of CaCCs has also been subject of controversial speculation. hCLCA1 had emerged 
as a possible candidate, as its expression had been demonstrated to be exclusively confined to the 
crypt, but was later shown to be a secretory protein rather than a channel [80]. Today, the list of 
candidates for CaCCs consists of TMEM16a, bestrophin-2, and hTTYH3 [81–86]. Functional evidence 
for their importance in intestinal chloride secretion has so far only been gained for TMEM16a in a 
knock-out mouse model [87]. Yet supplemental studies that define the significance of CaCCs in the 
human intestine remain to be conducted.  
ClC-2 channels may represent a third route for apical chloride secretion. CF mice with a mild 
intestinal phenotype showed residual apical chloride conductance, which was attributed to expression 
of ClC-2 [88,89]. However, additional disruption of ClC-2 in a ClC-2/CFTR double knock-out mouse 
failed to exacerbate intestinal symptoms in the affected animals [90]. Localization studies in human 
tissue  further  showed  a  supra-nuclear  localization  pattern  that  does  not  correlate  well  with  the 
postulated secretory function of the channel [91]. Despite the ambiguous evidence for the involvement 
of ClC-2 in intestinal ion handling, the purportedly specific ClC-2 agonist lubiprostone is in clinical 
use to ameliorate symptoms of constipation. A recent study, however, demonstrates that intact CFTR is 
necessary for lubiprostone to exert its effect, further challenging the suggested importance of ClC-2 
ion handling in the enterocyte [92].  
3. The Pathophysiology of Enterotoxin Mediated Diarrhea 
3.1. Enterotoxigenic E. coli 
Enterotoxigenic E. coli (ETEC) infection is one of the leading causes of diarrhea in the developing 
world. Children are especially susceptible to intestinal infection, with 280 million cases of ETEC 
related  diarrhea  occurring  each  year  in  children  under  the  age  of  five [93].  ETEC  infection  also 
accounts for 50–60% of all cases of traveler’s diarrhea, which amounts to about 60 million cases per 
year in total [94–96]. In light of these high incidence rates it comes as no surprise that ETEC infection 
takes its toll with an estimated 370,000 deaths each year, the vast majority of which are children [93].  
ETEC produces at least one of two defined enterotoxins: heat stable enterotoxins (ST) or heat labile 
enterotoxins (LT). LT exists in two classes, only one of which is associated with intestinal disease, 
namely LT-I. LT-I is a hetero-oligomeric holotoxin, composed of one A subunit and five identical B 
subunits and thus belongs to the family of AB5 enterotoxins [97]. Among other bacterial toxins, the 
AB5  enterotoxin  family  also  includes  cholera toxin  (CTX)  and  Shiga  toxin  (STX).  Because  these 
toxins exhibit a significant degree of homology in both sequence (the A1 subunits of CTX and LT-I Toxins 2010, 2                               
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have 78% sequence homology) and pathophysiology, we will regard LT-I and CTX as one entity with 
respect  to  their  cellular  mechanism  of  action [98].  The  crystal  structures  of  both  toxins  are  now 
available to us and may aid in further elucidating the sites of action [99–101]. It should be noted that 
disease  severity  in  ETEC  infection  is  generally  lower  than  in  cholera  infection.  While  the  basic 
mechanisms for this effect are not fully understood, it has been proposed that the efficiency of toxin 
secretion may differ between the two bacterial species [102]. For the pathophysiological processes 
underlying LT-I infection, please refer to the section on V. cholerae. 
ETEC produce ST enterotoxins in two variations: STa and STb. Consisting of only 18 or 19 amino 
acids, STs are considerably smaller in size than LTs and are monomeric in structure [103–107]. The 
STs contain six cysteine residues, forming three disulfide bonds [103,104,106,108,109]. The residues 
and bonds are responsible for the heat stability of the protein and were shown to be essential for its 
toxicity [108–110]. The structure of STs is shared to a significant degree with the heat stable toxins 
from V. cholerae O1/non-O1 and Yersinia enterocolitica [111–113]. Unlike LT-I, STs do not exert 
their toxic effects in the cytoplasm of the enterocyte, but rather bind to a receptor on the membrane 
surface. Receptor quantity decreases with age, which may account for the high prevalence and disease 
severity of ETEC mediated diarrhea in children [114]. The receptor has subsequently been cloned and 
identified  as  the  membrane-bound  guanylyl  cyclase  type  C  (GC-C),  which  is  comprised  of  an 
extracellular  receptor  domain,  a  single  membrane  spanning  domain,  and  an  intracellular  kinase 
homology domain followed by the guanylyl cyclase domain [115,116]. Stimulation of GC-C leads to 
an increase in intracellular cGMP concentrations, resulting in activation of PKA or cGMP-dependent 
protein  kinase  II  (cGK  II)  and  increased  chloride  secretion  through  apical  CFTR  channels 
[56,117,118]. Both kinases mediate CFTR activation and concomitant NHE3 inhibition via NHERF, 
leading to increased chloride secretion and reduced sodium absorption [17,19,56,119,120]. cGK (−/−) 
animals were further shown to secrete less fluid in response to STa exposure [118].  
Diarrhea  ensues  as  a  product  of  increased  luminal  osmolarity.  Apart  from  kinase  mediated 
activation, cGMP may influence channel gating directly by binding to CFTR [121]. As CFTR is the 
common endpoint for both CTX and STa mediated diarrhea, CF patients and transgenic CF mice seem 
to have an innate immunity against both toxins [122,123]. The exact binding site of STa to GC-C is 
well  characterized  by  the  use  of  receptor  mutagenesis  and  photoaffinity  labeled  STa [124,125]. 
Mutation  analysis  of  STa  has  further  revealed  that  the  central  -turn  region  of  the  protein  
(Asn
11–Cys
14) is responsible for GC-C binding and that this interaction is dependent on hydrophobic 
amino  acid  sidechains [126–129].  A  GC-C  (−/−)  model  has  helped  provide  us  with  compelling 
evidence  of  the  cyclases’s  involvement  in  the  process  of  STa  mediated  diarrhea,  as  the  affected 
animals were shown to be resistant against the effects of the toxin [130,131].  
Beside  STa,  the  endogenous  peptides  uroguanylin  and  guanylin,  which  are  implicated  in  the 
maintenance  of  salt  balance,  serve  as  physiological  activators  of  GC-C [132–136].  Guanylin  is 
significantly homologous  to  STa in  its  structure  and  also  relies  on disulfide linkages for receptor 
activation [137].  Membrane  guanylyl  cyclases  also  serve  as  peptide  hormone  receptors  regulating 
electrolyte homeostasis in other tissues. Atrio-natrioretic peptide, which is secreted by the atrium in 
response to increased atrial stretch, binds to a similar membrane guanylyl cyclase in the kidney [138]. 
GC-C has recently been identified as a pharmacological target in the treatment of constipation. The Toxins 2010, 2                               
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synthetic 14-peptide GC-C agonist linaclotide (formerly MD-1100) effectively alleviated symptoms of 
constipation in numerous clinical trials [139,140]. 
In addition to GC-C, several other STa receptors have been postulated to exist [141–144]. This 
hypothesis has recently been supported by the observation that STa can induce HCO3
- secretion in a 
non-cGMP, non-GC-C and non-CFTR dependent manner [145,146]. The fact that this HCO3
- secretion 
is not dependent on CFTR is especially remarkable, as intact CFTR is traditionally regarded to be a 
prerequisite for HCO3
- secretion [147].  
Currently, two pharmacological strategies have been employed to specifically counteract the effects 
of  STa:  (i)  inhibition  of  GC-C  and  its  signaling;  and  (ii)  inhibition  of  chloride  secretion  through 
CFTR [148–152].  The  group  of  pyridopyrimidine  derivatives  has  been  demonstrated  to  decrease 
cGMP levels in T84 cells and to decrease STa triggered fluid secretion in an isolated intestinal loop 
model by inhibition of GC-C [148,149]. Specificity of the substance is limited, as other GC family 
members (GC-A,B and soluble forms) were also inhibited [148]. In addition, the tyrphostin tyrosin 
kinase inhibitors and the membrane permeable nucleoside analog 2-chloroadenosine were shown to 
inhibit GC-C activity in a cultured cell model [150–152]. However, the most promising substances for 
inhibiting  STa  mediated  diarrhea  are  clearly  the  specific  CFTR  channel  inhibitors,  as  they  are  
non-absorbable  and  exert  their  effects  on-site  in  the  intestinal  lumen.  Except  for  one  study,  the 
majority of data has been generated in a CTX model, as CFTR represents the common endpoint for 
both CTX and STa mediated diarrhea [153]. Apart from specific treatment approaches, dietary calcium 
intake has been show to inhibit ETEC mediated diarrhea in human test subjects [154].  
Figure 1. Model summarizing cellular processes during STa mediated diarrhea. 
 
3.2. Vibrio Cholerae 
In 2008, over 190,000 cases of cholera were reported to the WHO [155]. It is safe to say that the 
actual  number  of  annual  symptomatic  V.  cholerae  infections  is  much  higher  as  a  result  of 
underreporting. Particularly disconcerting is the fact that on average the number of cholera cases has Toxins 2010, 2                               
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been on the rise in recent years [155]. As the disease is transmitted feco-orally, cholera is associated 
with poor sanitary conditions. Cholera outbreaks are thus grim companions of natural catastrophes, 
political instability and poverty. The disease itself is characterized by a watery diarrhea with typical 
rice-water stools. The fulminant onset of diarrhea is extremely abrupt and the massive fluid loss of up 
to 1liter/h can be lethal within hours as a result of dehydration [156]. Although aggressive rehydration 
therapy has proven to be an effective countermeasure, the acute nature of the disease calls for rapid 
accessibility to treatment, which is often a challenging endeavor in underdeveloped regions.  
The effects of cholera are mediated by CTX, which is secreted by the bacterium. Once secreted, the 
B subunits of CTX bind to the membrane associated ganglioside GM1, which serves as a receptor for 
CTX on the cell surface. The number of B subunits correlates with toxicity, presumably by facilitating 
uptake  through  clustering  of  multiple  GM1s [157].  Following  binding,  the  CTX-GM1  complex 
undergoes endocytosis and embarks on a true odyssey through the enterocyte before the toxin finally 
exerts its pathological effects in the cytosol. The trafficking of CTX through the cell has received an 
extensive amount of scientific attention, with the hope of identifying a possible pharmacological target 
for the treatment of LT-I and CTX related diarrhea. The trafficking process is reviewed in great detail 
elsewhere  and  will  only  be  described  briefly  in  this  review [158,159].  After  endocytosis,  CTX  is 
trafficked via endosomes to the trans-Golgi network in an actin dependent manner [158–160]. The 
toxin subsequently continues its journey to the ER, where protein disulfide isomerase (PDI) unfolds 
the enzymatically active A1 chain of the holotoxin, allowing A1 to be released from the ER into the 
cytosol. The pathway through which A1 release occurs is not yet fully understood [158]. Once in the 
cytosol, A1 starts to exert its toxic effects. One of the earliest observations on the impact of CTX was 
made in Ussing chamber experiments on isolated rabbit ileal mucosa, demonstrating an inhibition of 
short circuit current (SCC; an indicator for chloride secretion) following toxin exposure [161]. Similar 
changes  could  be  elicited  by  cAMP,  suggesting  that  CTX  exerts  its  action  through  elevation  of 
intracellular cAMP concentrations [161]. The A1 chain elevates intracellular cAMP concentrations by 
activating  the  alpha  subunit  of  a  G-Protein  (Gs)  which  in  turn  increases  adenylyl  cyclase 
activity [102,162]. Gs loses its intrinsic GTPase activity by A1 mediated ADP ribosylation of an 
arginine residue, resulting in prolonged activity of Gs [163–165]. Cells from mice lacking the enzyme 
which antagonizes ADP ribosylation (ADP-ribosyl protein hydrolase) are verifiably more sensitive to 
CTX [166]. As outlined above, cAMP is an activator of apical CFTR channels, which was postulated 
to account for the observed changes in potential difference and SCC [102]. CTX triggered elevations 
of cAMP levels further inhibit Na
+ uptake by NHE in the villus cell and thereby increase the osmotic 
driving force for fluid secretion [167,168].  
Serotonin (5-HT) release from enterochromaffin cells has also been implicated in the mechanism of 
action of CTX [169–171]. A CTX mediated increase of 5-HT release was observed in a preparation of 
human ileum [169]. Application of the 5-HT3 receptor antagonist granisetron resulted in a decrease of 
both 5-HT release and fluid secretion in isolated rat intestinal segments [172]. In addition, CTX is 
capable  of  modulating  the  immune  response  of  the  host  by  eliciting  IL-6  secretion  from  the 
enterocytes, depleting the reserves of CD8+ intraepithelial lymphocytes and by inhibiting CD4+ and 
CD8+ lymphocytes [173–176]. A recent study has also investigated the gene expression patterns in 
response to CTX exposure by micro-array analysis [177]. The affected genes are speculated to play a 
role in the innate defense mechanism of the exposed cell [177].  Toxins 2010, 2                               
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Prostaglandins of the E family (PGE) were shown to play an important role in the action of CTX 
mediated diarrhea. An increase of PGE synthesis was observed in rat and pig ileum in response to 
CTX exposure [178–180]. PGE is also able to induce fluid secretion in unexposed tissue [178,179] 
(this view has also been opposed by Hudson et al. [181]). The role of PGE in the genesis of cholera is 
further emphasized by the successful inhibition of secretion following treatment with cyclooxygenase 
(COX) inhibitors [182,183]. Cells from COX (−/−) animals, however, demonstrated no significantly 
different behavior from wild-type cells in terms of pathological fluid secretion [182]. To the present 
day, the exact relationship and hierarchy between the cAMP, PGE and 5-HT signals have not been 
thoroughly defined [102,184]. 
Although the mechanisms of intestinal electrolyte secretion are fairly well understood, the exact 
route of the ensuing water movement is still unknown [2]. Aquaporin water channels (AQP) have 
emerged as possible candidates for transcellular water movement [2]. Several groups have set out to 
investigate their role in cholera. CTX was shown to modulate permeability of several AQPs in an 
oocyte overexpression system [185]. AQP8 in particular is expressed in the intestine and was shown to 
be regulated by cAMP in the liver [186,187]. Furthermore, observations in rat intestine verify down 
regulation of AQP8 following CTX exposure [188](conversely, AQP10 is down regulated in human 
cholera patients [189]). However, results in a recent AQP8 (−/−) model do not support the hypothesis 
that AQP8 serves as an important route for water secretion in cholera, as the affected mice showed a 
normal secretory response to CTX [188]. 
Chloride secretion through CFTR is canonically regarded to be a major endpoint of CTX toxicity, 
presumably via elevation of intracellular levels of cAMP [102]. An early observation emphasizing this 
theory was made in CF mice that secreted less intestinal fluid in response to CTX [190]. Subsequently, 
it has been argued that the high prevalence of CF in our population may be a result of an innate 
resistance  to  cholera,  thereby  conferring  an  evolutionary  advantage  on  heterozygous  mutation 
carriers [190]. CFTR has evolved into a popular target for the potential treatment of cholera. Currently, 
three groups of specific CFTR inhibitors exist. The thiazolidinone CFTRInh-172 was shown to reduce 
CTX  stimulated  fluid  secretion,  assessed  by  intestinal  weight  measurements,  by  as  much  as 
90% [153,191]. In vivo administration of the herbal extract SP-303 also yielded significantly less fluid 
accumulation, employing a comparable experimental approach [192]. The formulation of the original 
substance has recently been improved; however, in vivo data are not yet available [193]. The glycine 
hydrazide GlyH-101 was also tested in a closed loop model and reduced CTX induced fluid secretion 
by 80% [194]. Nonetheless, none of these substances is currently in clinical use. In the absence of a 
specific treatment for cholera, aggressive rehydration with ORS solutions remains the most crucial 
countermeasure against the massive fluid loss that occurs in the course of the disease. The efficacy of 
ORS  treatment  is  exemplified  in  a  case  study  from  the  70s  in  which  cholera  mortality  could  be 
decreased among Bangladesh refugees to 3.6% by administration of ORS, compared to 30% in similar 
refugee  camps  that  relied  purely  on  intravenous  fluid  substitution  therapy [195].  In  addition  to 
rehydration  therapy,  a  single-dose  administration  of  azithromycin  has  been  shown  to  ameliorate 
disease severity [196,197]. Apart from these strategies, our specific therapeutic resources are limited. 
A  supplemental  pharmacological  approach  is  still  desirable.  The  specific  CFTR  inhibitors  may 
represent a remedy for this need, but their clinical potency still remains to be reviewed. Toxins 2010, 2                               
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Figure 2. Model summarizing cellular processes during CTX mediated diarrhea. 
 
3.3. Rotavirus  
Rotavirus infection is the leading cause of diarrhea related hospitalization in children (<5 years)[198,199]. 
Estimations assert that 611,000 childhood deaths are caused annually by rotavirus, 80% of which occur 
in  developing  countries [200].  Rotavirus  infection  is  a  global  phenomenon,  and  the  industrialized 
world is not exempt from its burden. In the US alone, 60,000 hospitalizations per year are attributable 
to the virus, although mortality is substantially lower with 37 deaths annually [201]. 
The RNA of rotavirus encodes six viral proteins (VPs) and six nonstructural proteins (NSPs). One 
of the NSPs, namely NSP4, is a viral protein that induces diarrhea [202,203]. Although several other 
mechanisms, such as activation of the enteric nervous system, secretion of chemokines and epithelial 
ischemia, contribute to the diarrheagenic effects of rotavirus, we will limit our scope on the enterotoxin 
NSP4 [204–206]. NSP4 is a multifunctional protein and, besides its role as an enterotoxin, also serves 
as a receptor on the ER that mediates translocation of viral particles between cytosol and ER [207–209]. 
Recent data suggest that NSP4 can be trafficked from the ER to the plasma membrane where it is 
secreted  by  the  infected  enterocyte [210–213].  Given  the  fairly  recent  discovery  of  NSP4,  our 
knowledge  about  its  enterotoxic  nature  is  still  limited.  We  know  that  NSP4  can  directly  induce 
diarrhea and that this effect is not mediated through CFTR, as (−/−) animals were still susceptible to its 
effects [203,214]. In addition, it has been extensively described that NSP4 can increase intracellular 
Ca
2+ concentrations [202,215,216]. It has recently been speculated that upregulation of the MS4A2 
gene, which encodes a protein with a calcium channel activity, could play a role in this process [217]. 
Elevations of intracellular Ca
2+ can activate CaCCs and may explain the vulnerability of CFTR (−/−) 
animals to NSP4. However, evidence for direct NSP4 induced intestinal chloride secretion is still 
scarce.  So  far,  Ussing  chamber  studies  in  a  cell  culture  model  demonstrated  an  NSP4  dependent 
increase in SCC and I
- imaging revealed that NSP4 causes non-CFTR mediated anion permeability in 
isolated murine crypts [214,218].  
A direct inhibition of SGLT1 has also been observed and may cause osmotic diarrhea by impaired 
uptake of Na
+ and glucose, rather than by increased secretion [219]. A different group has reported that Toxins 2010, 2                               
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NSP4 can increase paracellular permeability in a polarized cell model [220]. In summary, conclusive 
information on the action of NSP4 on enterocyte ion transport is not available, although changes in 
Ca
2+ homeostasis seem to be involved.  
As a result of the plethora of cellular mechanisms that are affected by Rotavirus infection, no 
specific treatment model exists. Yet, remarkable progress has been made in the prevention of the 
disease with the introduction of Rotavirus vaccines [221].  
Figure 3. Model summarizing cellular processes during NSP4 mediated diarrhea. 
 
4. Conclusions 
Our knowledge of the molecular mechanisms underlying ETEC, cholera, and Rotavirus mediated 
diarrhea has massively improved over the last years. Paradoxically, our arsenal of potential specific 
therapeutic  approaches  is  still  small  by  comparison.  The  non-absorbable  CFTR  inhibitors  can  be 
regarded  as  the  most  promising  advance  in  the  direction of  targeted treatment,  but  proof  of  their 
clinical efficacy and benefit is not yet available. Although unspecific, the advent of ORS represents the 
most revolutionary progress that has been achieved in terms of averting the lethal consequences of 
ADI in the past decades. The millions of remaining ADI related deaths, however, are a sad reminder 
that complimentary therapeutic approaches need to be developed and that accessibility to treatment has 
to be optimized.  
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